| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 10/31/2001 | EP0966291B1 Medicinal preparation containing a lipophilic inert gas |
| 10/31/2001 | EP0894043B1 Method of forming articles and patterning surfaces via capillary micromolding |
| 10/31/2001 | EP0840634B1 Transcorneal drug-release system |
| 10/31/2001 | EP0836473B1 Ring-shaped devices |
| 10/31/2001 | EP0812186B1 Method for loading lipid vesicles |
| 10/31/2001 | EP0809486B1 Bio-erodible ophthalmic shield |
| 10/31/2001 | EP0774957B1 Aqueous foamable composition |
| 10/31/2001 | EP0760649B1 Fluticasone propionate formulations |
| 10/31/2001 | EP0716598B1 Pharmaceutical preparations for the targeted treatment of morbus crohn and colitis ulcerosa |
| 10/31/2001 | EP0703779B1 Enzyme-containing tablets and process of preparation thereof |
| 10/31/2001 | EP0641183B1 Coated transplant and method for making same |
| 10/31/2001 | EP0627918B1 New use of omega-3-fatty acids |
| 10/31/2001 | DE10027258C1 Transdermal therapeutic system, for local/systemic delivery of non-steroidal antiinflammatory agents, comprises a permeable, elastic water and air permeable backing layer and an impermeable two-phase drug-containing matrix layer |
| 10/31/2001 | DE10019311A1 Transdermal therapeutic system used for treating hypertension has reservoir layer based on hydrophilic polymer and/or containing saturated and unsaturated fatty acids |
| 10/31/2001 | DE10018022A1 Use of a lung surfactant composition to produce medicaments for the prophylaxis or early therapy of acute lung disorders in mammals |
| 10/31/2001 | CN2456695Y Chemical therapy adhesive film |
| 10/31/2001 | CN1320145A Pressure-sensitive adhesive composition and moisture-premeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation |
| 10/31/2001 | CN1320033A Plaster containing medicament, with three functional layers |
| 10/31/2001 | CN1320032A Alginate capsules for use in the treatment of brain tumor |
| 10/31/2001 | CN1319615A Hard capsule containing vinyl ester and polyether polymer, its use and production process |
| 10/31/2001 | CN1319424A Anticancer medicine of Annona squamose extractum and preparation method thereof |
| 10/31/2001 | CN1319416A Liquid medicine for treating influenza virus and preparation process thereof |
| 10/31/2001 | CN1319415A Pill medicine for treating cardio-cerebro vascular diseases |
| 10/31/2001 | CN1319398A Fructose-1,6-magnesium diphosphate injection and productive method thereof |
| 10/31/2001 | CN1319396A Medicinal composition |
| 10/31/2001 | CN1319395A Refapentine or rifampin liposome perfusate, injection and preparation process thereof |
| 10/31/2001 | CN1319394A Easy effervescent, moistureproof antiseptic antiphlogistic tablet and preparation process thereof |
| 10/31/2001 | CN1319391A Active content contained floating form having polyacetic vinylester and polyvinyl pyrrolidone, its preparation and use |
| 10/31/2001 | CN1319343A Health care food having functions of reducing weight and preventing cardiovascular disease |
| 10/31/2001 | CN1073991C Antilysin used reverse transcription enzyme inhibitor crystallizing technology |
| 10/31/2001 | CN1073978C Polyol compoistion produced by CO-spray-drying |
| 10/31/2001 | CN1073857C Freeze-dried live attenuated hepatitis A vaccine and its preparation |
| 10/31/2001 | CN1073855C 芦荟组合物 Aloe composition |
| 10/31/2001 | CN1073851C High efficiency ointment for curing beri-beri (tinea pedis) |
| 10/31/2001 | CN1073850C Desert cistanche granule |
| 10/31/2001 | CN1073847C Traditional Chinese medicine for curing hepatitis |
| 10/31/2001 | CN1073845C Liniment film for onychomycosis and its preparation technology |
| 10/31/2001 | CN1073842C Cosmetic or topical use of an aqueous dispersion |
| 10/30/2001 | US6310188 Preparing polysaccharides and mucopolysaccharides; heat crustacean shells, cool in liquid nitrogen, recover mucopolysaccharides and polysaccharides |
| 10/30/2001 | US6310100 Method of treating hypertension |
| 10/30/2001 | US6310094 Ready-to-use esmolol solution |
| 10/30/2001 | US6310089 Composition for the administration of a D1-agonists |
| 10/30/2001 | US6310053 Complexed with an equimolar amount of a magnesium compound, and solubilized in a water miscible solvent system comprising glycerol formal and polyethylene glycol in different volumes depending on molecular weight, and a ph modifier reduction |
| 10/30/2001 | US6310038 Pulmonary insulin crystals |
| 10/30/2001 | US6309671 Stable glassy state powder formulations |
| 10/30/2001 | US6309669 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| 10/30/2001 | US6309668 Abuse resistant tablets |
| 10/30/2001 | US6309666 Hard capsule containing acidic substance to control release, polymer film soluble at low ph, enteric coating film |
| 10/30/2001 | US6309665 Composition with sustained release of active principle, capable of forming a microemulsion |
| 10/30/2001 | US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 10/30/2001 | US6309655 Self-indicating cosmetic composition |
| 10/30/2001 | US6309642 Peptides which mimic candida carbohydrate epitopes and their use in a vaccine |
| 10/30/2001 | US6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| 10/30/2001 | US6309630 Non-steroidal anti-inflammatory ophthalmic suspensions |
| 10/30/2001 | US6309624 Particulate medicament in an aerosol formulation with a propellant and co-propellant |
| 10/30/2001 | US6309623 Plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 mum and comprising at least one bioactive agent wherein said suspension medium comprises at least one propellant |
| 10/30/2001 | US6309569 Encapsulation of bioactive agents |
| 10/30/2001 | US6309380 Drug delivery via conformal film |
| 10/30/2001 | US6308434 Spray drying method |
| 10/30/2001 | CA2175830C Application of trace elements to animals |
| 10/30/2001 | CA2165265C High hydroxyacid water in oil emulsion cosmetic or dermatologic composition |
| 10/30/2001 | CA2150617C Nanoerythrosome as bioactive agent carrier |
| 10/30/2001 | CA1341313C Photostable filtering cosmetic emulsion based on beneze-1,4-di(3-methylidene-10-campho-sulfonic) acid and at least one liposoluble uv-a filter |
| 10/25/2001 | WO2001079525A2 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 10/25/2001 | WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 10/25/2001 | WO2001079315A1 Polylactide/dextran graft co-polymers for biomaterial and tissue engineering applications |
| 10/25/2001 | WO2001079302A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component |
| 10/25/2001 | WO2001078761A2 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
| 10/25/2001 | WO2001078746A1 Respiratory compositions |
| 10/25/2001 | WO2001078745A1 Medical combinations comprising formoterol and fluticasone proprionate |
| 10/25/2001 | WO2001078744A1 Medical combinations comprising formoterol and mometasone |
| 10/25/2001 | WO2001078743A1 Medical combinations comprising tiotropium and mometasone |
| 10/25/2001 | WO2001078742A1 Medical combination comprising salmeterol and budesonide |
| 10/25/2001 | WO2001078741A1 Medical combinations comprising tiotropium and budesonide |
| 10/25/2001 | WO2001078740A1 Medical combinations comprising mometasone and salmeterol |
| 10/25/2001 | WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 10/25/2001 | WO2001078738A1 Medical compositions comprising (r,r)-formoterol and rofleponide |
| 10/25/2001 | WO2001078737A1 Medical combinations comprising formoterol and budesonide |
| 10/25/2001 | WO2001078736A1 Medical combinations comprising tiotropium and rofleponide |
| 10/25/2001 | WO2001078735A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| 10/25/2001 | WO2001078732A1 Ciprofloxacin infusion solutions having a good storage stability |
| 10/25/2001 | WO2001078731A1 Ciprofloxacin infusion solutions with improved storage life |
| 10/25/2001 | WO2001078730A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 10/25/2001 | WO2001078727A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 10/25/2001 | WO2001078725A2 Modified release formulations containing a hypnotic agent |
| 10/25/2001 | WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2 |
| 10/25/2001 | WO2001078716A1 Solid dispersion with improved absorbability |
| 10/25/2001 | WO2001078706A2 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 10/25/2001 | WO2001078696A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078695A2 Pharmaceutical formulations for dry powder inhalers |
| 10/25/2001 | WO2001078694A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078693A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 10/25/2001 | WO2001078692A2 Membrane delivery system |
| 10/25/2001 | WO2001078691A1 Therapeutic patch containing a liquid or gel organic compound as a carrier |
| 10/25/2001 | WO2001078690A1 Patch containing anti-inflammatory agent |
| 10/25/2001 | WO2001078689A2 Particulate composition |
| 10/25/2001 | WO2001078688A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 10/25/2001 | WO2001078687A1 Injectable sustained release pharmaceutical composition and processes for preparing the same |
| 10/25/2001 | WO2001078686A1 Time-release coated solid compositions for oral administration |
| 10/25/2001 | WO2001078685A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing bmp-4 |